REFERENCES
- Bartsch, C, et al. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the
prostate: relationship with the pituitary hormones. J Pineal Res, Vol. 2, No. 2, 1985, pp. 121-32
- Bartsch, C, et al. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate
cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta, Vol. 209,
August 31, 1992, pp. 153-67
- Erren, TC and Piekarski, C. Does winter darkness in the Arctic protect against cancer? The melatonin hypothesis
revisited. Med Hypotheses, Vol. 53, July 1999, pp. 1-5
- Moretti, RM, et al. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep, Vol. 7,
March-April 2000, pp. 347-51
- Marelli, MM, et al. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer
cells. Prostate, Vol. 45, No. 3, November 1, 2000, pp. 238-44
- Shiu, SY, et al. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a
patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res, Vol. 35, October 2003, pp. 177-82
- Sainz, RM, et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a
receptor and PKA independent mechanism. Prostate, Vol. 63, No. 1 April 1, 2005, pp. 29-43
- Molis, TM, et al. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in
human breast cancer. J Pineal Res, Vol.18, March 1995, pp. 93-103
- Davis, S, et al. Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in
women. American Journal of Epidemiology, Vol. 154, October 1, 2001, pp. 591-600
- Kliukiene, J, et al. Residential and occupational exposures to 50-Hz magnetic fields and breast cancer in women: a
population-based study. American Journal of Epidemiology, Vol. 159, May 1, 2004, pp. 852-61
- Davis, S, et al. Effects of 60-Hz magnetic field exposure on nocturnal 6-sulfatoxymelatonin, estrogens, luteinizing
hormone, and follicle-stimulating hormone in healthy reproductive-age women: results of a crossover trial. Ann
Epidemiol, January 31, 2006
- Feychting, M and Forssen, U. Electromagnetic fields and female breast cancer. Cancer Causes Control, Vol. 17,
No. 4, May 2006, pp. 553-8
- Hansen, J. Increased breast cancer risk among women who work predominantly at night. Epidemiology, Vol. 12,
January 2001, pp. 74-77
- Jasser, SA, et al. Light during darkness and cancer: relationships in circadian photoreception and tumor biology.
Cancer Causes Control, Vol. 17, No. 4, May 2006, pp. 515-23
- Stevens, RG. Artificial lighting in the industrialized world: circadian disruption and breast cancer. Cancer Causes
Control, Vol. 17, No. 4, May 2006, pp. 501-07
- Bartsch, C and Bartsch, H. The anti-tumor activity of pineal melatonin and cancer enhancing life styles in
industrialized societies. Cancer Causes Control, Vol. 17, No. 4, May 2006, pp. 559-71
- U.S. Department of Energy. Environment, Safety, and Health Manual. Document 20.07 Nonionizing Radiation and
Fields (Electromagnetic Fields and Radiation with Frequencies Below 300 GHz), April 5, 2005, Appendix A
http://www.llnl.gov/es_and_h/hsm/doc_20.07/doc20-07.pdf
|